-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense Therapeutics Locks Database for Phase 2 Alzheimer's Trial with Topline Results Expected in 2026

Reuters·12/08/2025 13:01:48

Please log in to view news